Laddar populära aktier...
NEX-22 is progressing as expected, with the last patient in Phase I treated, results anticipated lat...
Sales -3%, EBITA +1% vs. ABGSCe, book-to-bill 0.99x Expects decline to decelerate from here, return ...
Redeye states that the Q3 report was solid, with ad revenues returning to y/y growth, while recurrin...
Relais Group's Q3 report fell slightly short of LSEG Data & Analytics consensus.
Redeye provides a research update following Catella's Q3 2024 report.
Redeye provides an update following Optomed’s Q3 report.
Redeye maintains a positive view of Transtema following a softer Q3 than expected due to weak margin...
Nettoomsättningen för det tredje kvartalet uppgick till 0,93 MSEK (0,83), vilket var en ökning om 8,...
20% revenue beat driven by high watch sales, EBITDA 66% above Opex was above, but likely due to extr...
Prospekterings- och gruvutvecklingsbolaget Bluelake Minerals bearbetningskoncession för Levi blev go...
Suominen had some production issues in Q3, and even if those no longer bother valuation begins to lo...
CapMan’s Q3 results were below our and consensus expectations.
After the recent rights issue, Ascelia has SEK 95.
Redeye sees a Q3 report on the soft side from Transtema.
Redeye provides its initial take on Acarix’s Q3 report, which showed revenues falling short of estim...
